Skip to content

Physiotherapists prescribing medications to manage pain in emergency departments and outpatient clinics

In patients presenting to emergency departments or orthopaedic clinics with musculoskeletal conditions, does physiotherapists prescribing medications to manage pain result in adverse events?

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12615000525583
Enrollment
1220
Registered
2015-05-26
Start date
2017-05-11
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study aims to investigate the safety and patient experience of prescribing by credentialed physiotherapists. Patients attending emergency departments and outpatient clinics with musculoskeletal conditions will be prescribed medications from a limited list to manage pain and support physiotherapy treatment.

Interventions

Assessment and management of patient presentation in accordance with clinical guidelines by physiotherapists in the emergency department or orthopaedic clinic. This may involve mobilisation, massage, exercise therapy, stretches, advice and provision of the following medications, at the discretion of the physiotherapist, for the management of pain: Paracetamol (oral tablet) Paracetamol and Codeine (oral tablet) Diclofenac sodium (oral tablet) Lignocaine 1 or 2% (subcutaneous or intra-articular i

Assessment and management of patient presentation in accordance with clinical guidelines by physiotherapists in the emergency department or orthopaedic clinic. This may involve mobilisation, massage, exercise therapy, stretches, advice and provision of the following medications, at the discretion of the physiotherapist, for the management of pain: Paracetamol (oral tablet) Paracetamol and Codeine (oral tablet) Diclofenac sodium (oral tablet) Lignocaine 1 or 2% (subcutaneous or intra-articular injection) Nitrous Oxide up to 70% (inhaled gas) Ibuprofen (oral tablet) Betamethasone injection 5.7mg/ml (intra-articular injection) Methylprednisolone acetate 40mg/ml 1ml (intra-articular injection) Amitriptyline hydrochloride (oral tablet)

Sponsors

QEII Jubilee Hospital
Lead SponsorHospital

Study design

Allocation
Non-randomised trial
Primary purpose
Treatment

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Male or female aged 18 years and over 2. There is a requirement to prescribe medication to the extent necessary for the physiotherapist to practice physiotherapy, 3. Peripheral musculoskeletal injuries / conditions / symptoms: sprains, strains, suspected simple fractures, subacute and chronic tendinitis, tendinosis, tenosynovitis, bursitis, tenovaginitis (trigger finger, DeQuervain’s) and osteoarthritic arthritic joint disease OR Musculoskeletal pain of spinal origin 4. Ability to provide informed consent and accurately follow the instructions of the researcher 5. Attending emergency department or outpatient clinics for the management of their musculoskeletal condition

Exclusion criteria

1. Open wounds 2. Infection 3. Active Inflammatory disease as the primary reason for intervention (i.e. rheumatoid disease and the seronegative arthritides) 4. Neoplastic disease as the primary reason for intervention 5. Cardiovascular disease as the primary reason for intervention 6. Metabolic disease as the primary reason for intervention 7. Central nervous system disorders as the primary reason for intervention 8. Cauda equina injury 9. Acute head injury 10. Loss or altered state of consciousness 11. Pain of non-mechanical origin 12. Polytrauma and high energy injuries including falls from above standing height 13. Respiratory distress 14. Abdominal pain 15. Women who are pregnant and the human foetus

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026